# US 2010/0262115 A1 · Nanoparticles for cancer sonodynamic and photodynamic therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0262115 A1
- Document ID: US20100262115A1
- Status: Published application
- Kind: A1
- Application number: 12/755,942
- Filed: 2010-04-07
- Published: 2010-10-14
- Earliest claimed: 2009-04-07
- Assignees: Intelligentnano Inc.; Quest Pharmatech Inc.
- Inventors: Ragupathy MADIYALAKAN; James XING; Thomas WOO; Eric SWANSON
- Web page: https://patentgrep.com/patent/US20100262115A1

## CPC

- A61K 41/0033: {Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds (ultrasound therapy per se A61N7/00)}
- A61K 9/0009: {involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to nanoparticles comprising a cancer therapeutic, pharmaceutical compositions comprising same, and methods for using same for drug delivery and ultrasound or light-based treatment of cancer.

## Claims

### Claim 1

A nanoparticle comprising an inner volume comprising a hypocrellin-B derivative and a polyvinylpyrollidone shell encapsulating the inner volume.

### Claim 2 (depends on 1)

The nanoparticle of claim 1, wherein the hypocrellin-B derivative is SL052.

### Claim 3 (depends on 1)

The nanoparticle of claim 1, bound to a detectable labelling agent.

### Claim 4 (depends on 3)

The nanoparticle of claim 3, wherein the detectable labelling agent is selected from a fluorescent or other light-emitting marker, a radioactive tracer, or a contrast agent.

### Claim 5 (depends on 1)

The nanoparticle of claim 1, bound to a selective targeting moiety such as an antibody or an antibody fragment.

### Claim 6 (depends on 1)

The nanoparticle of claim 1 in combination with one or more pharmaceutically acceptable carriers to form a pharmaceutical composition for treating tumors.

### Claim 7 (depends on 1)

A method of treating a tumor in a subject comprising:
administering a nanoparticle claimed in claim 1; and
applying ultrasound or light to the tumor, or ultrasound and light to the tumor;
wherein the nanoparticle achieves a cytotoxic effect to tumor cells upon exposure to the ultrasound or light.

### Claim 8 (depends on 7)

The method of claim 7, wherein the tumor is selected from a tumor of the brain, lung, breast, pancreas, kidney, colon, rectum, ovary, cervix or prostate.

### Claim 9 (depends on 7)

The method of claim 7, wherein the ultrasound or light is applied after an incubation period following administration of the nanoparticle.

### Claim 10 (depends on 9)

The method of claim 9, wherein the incubation period following application of ultrasound is at least thirty minutes.

### Claim 11 (depends on 9)

The method of claim 9, wherein the incubation period following application of ultrasound is at least two hours.

### Claim 12 (depends on 9)

The method of claim 9, wherein the incubation period following application of light is at least four hours.

### Claim 13 (depends on 7)

The method of claim 7, wherein the nanoparticle is bound to a detectable labelling agent.

### Claim 14 (depends on 13)

The method of claim 13, wherein the detectable labelling agent is selected from a fluorescent or other light-emitting marker, a radioactive tracer, or a contrast agent.